Novartis ‘disappointed’ and ‘surprised’ by NICE CAR-T call
NICE has deemed Novartis’ CAR T-cell therapy Kymriah too expensive for the UK market.
Top Headlines
Global Industry News
-
Siga signs $629m contract with BARDA for smallpox drug stockpiling
from in-PharmaTechnologist.com
-
Switzerland to Canada: GSK transfers Voltaren tech for local supply
from in-PharmaTechnologist.com
-
Phesi files patent for clinical trial protocol development method, system
from Outsourcing-Pharma.com
-
GeneOne signs licensing agreement for RNA development
from Outsourcing-Pharma.com
Hot Topics
-
Abzena announces licensing agreement for T-cell engineering
Cell & Gene Therapies
-
Partnership to provide oncology portfolio with a translational platform
Antibody-Drug Conjugates
-
Oncology vaccine ensured 100% survival rate in lab studies
Cell & Gene Therapies
-
Boehringer buys ViraTherapeutics to help make ‘cold’ tumours ‘hot’
Pipelines
